You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ESCC

Showing 26 - 50 of 250
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ESCC or Esophageal Adenosquamous Carcinoma Trial in Guangzhou (HLX07+HLX10+ Cisplatin+5-FU, HLX07)

Recruiting
  • ESCC or Esophageal Adenosquamous Carcinoma
  • HLX07+HLX10+ Cisplatin+5-FU
  • HLX07
  • Beijing, Beijing, China
  • +16 more
Aug 25, 2022

Esophageal Squamous Cell Carcinoma Abdominal Stage 0 Trial in Guangzhou (PD-1 Inhibitors, Irinotecan, Capecitabine tablets)

Recruiting
  • Esophageal Squamous Cell Carcinoma Abdominal Stage 0
  • PD-1 Inhibitors
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 20, 2023

Esophagus SCC Trial in Jinan (Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin)

Withdrawn
  • Esophagus SCC
  • Sintilimab Injection plus Paclitaxel and Cisplatin
  • Paclitaxel and Cisplatin
  • Jinan, Shandong, China
    Qilu Hospital of Shandong University
Apr 19, 2022

Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer Trial in Guangzhou (drug, radiation, procedure)

Recruiting
  • Squamous Cell Esophageal Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 11, 2022

Esophageal Squamous Cell Carcinoma Trial (QL1706)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Aug 4, 2022

Esophageal Squamous Cell Carcinoma Trial in Chengdu (OCDC vaccine; NeoDC vaccine)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • OCDC vaccine; NeoDC vaccine
  • Chengdu, Sichuan, China
    West China Hospital
Mar 30, 2022

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,

Recruiting
  • The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
  • Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
  • Hanzhou, Zhejiang, China
    Lulu Liu
Jul 14, 2023

ESCC Trial (Tislelizumab combined with chemoradiotherapy)

Not yet recruiting
  • ESCC
  • Tislelizumab combined with chemoradiotherapy
  • (no location specified)
Sep 18, 2022

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Dec 6, 2022

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Cisplatin+Capecitabine+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Zhengzhou, China
    The First Affiliated Hospital of Zhengzhou University
Aug 19, 2021

Esophageal Squamous Cell Carcinoma Trial (Anlotinib+TQB2450)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Feb 8, 2022

Esophageal Squamous Cell Carcinoma Trial in Tokyo (Chemoradiotherapy)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chemoradiotherapy
  • Tokyo, Japan
    National Cancer Center Hospital
Apr 5, 2022

ESCC, Adjuvant Treatment, Lymph Node Positive Trial in Tianjin (Pembrolizumab Injection [Keytruda])

Recruiting
  • ESCC
  • +3 more
  • Pembrolizumab Injection [Keytruda]
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Apr 26, 2021

Esophageal Cancer Trial in Shijiazhuang (Camrelizumab)

Recruiting
  • Esophageal Cancer
  • Shijiazhuang, Hebei, China
    Fourth Hospital of Hebei Medical University
Dec 8, 2021

Esophageal Squamous Cell Carcinoma Trial in Chengdu (Tislelizumab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Feb 8, 2022

Esophageal Squamous Cell Carcinoma Trial (Decitabine plus Penpulimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Decitabine plus Penpulimab
  • (no location specified)
Feb 23, 2022

Esophageal Squamous Cell Carcinoma Trial in Hanzhou, Ningbo (Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Radiotherapy
  • +2 more
  • Hanzhou, Zhejiang, China
  • +2 more
Aug 16, 2022

Esophageal Squamous Cell Carcinoma Trial in Chengdu (Tirelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Feb 8, 2022

18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Dynamic PET/CT
  • (no location specified)
Mar 10, 2022

Esophageal Squamous Cell Carcinoma, Stage III Trial in Tianjin (Pembrolizumab Injection [Keytruda])

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Stage III
  • Pembrolizumab Injection [Keytruda]
  • Tianjin, Tianjin, China
    Department of minimally invasive esophageal surgery, Tianjin Med
Mar 9, 2022

Locally Advanced Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib)

Recruiting
  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 16, 2022

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Nivolumab, Cisplatin, Paclitaxel)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, China
    180 Fenglin Road
Jun 12, 2022

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Two-Field lymph node dissection, Three-Field lymph node dissection)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Two-Field lymph node dissection
  • Three-Field lymph node dissection
  • Shanghai, Shanghai, China
    Shanghai Zhongshan Hospital
Jun 15, 2022

NSCLC, SCLC, CRPC Trial in Tianjin (JAB-8263)

Recruiting
  • NSCLC
  • +7 more
  • Tianjin, Tianjin, China
    Tianjin
Mar 11, 2022

Esophageal Squamous Cell Carcinoma Trial in Tianjin (biological, drug, radiation)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Pembrolizumab
  • +3 more
  • Tianjin, Tianjin, China
    Department of minimally invasive esophageal surgery, Tianjin Med
May 26, 2022